Emibetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MET/RCCP2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.